Ignite Creation Date:
2024-07-17 @ 11:02 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06464068
Status:
RECRUITING
Last Update Posted:
2024-06-18
First Post:
2024-06-07
Brief Title:
AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA
Sponsor:
Gruppo Oncologico Italiano di Ricerca Clinica
Organization:
Gruppo Oncologico Italiano di Ricerca Clinica
Study Overview
Official Title:
AGNOSTIC THERAPY IN A PHASE II MULTICENTER SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DURVASCC
Brief Summary:
This is a phase II single-arm multicenter study to evaluate the activity and safety of durvalumab in combination with carboplatin or cisplatin plus etoposide in patients with treated ES-EPSCC
Detailed Description:
All drugs will be administered intravenously Induction treatment will be administered on a 21-day cycle for four cycles and will consist of
etoposide 80-100 mgm² administered on days 1-3 of each 21-day cycle
investigators choice of either carboplatin area under the curve 5-6 mgmL per min or cisplatin 75-80 mgm² administered on day 1 of each cycle
durvalumab 1500 mg every 3 weeks in combination with chemotherapy induction phase followed by maintenance phase with durvalumab 1500 mg every 4 weeks Patients will continue treatment until disease progression per investigator assessment unacceptable toxicity or other discontinuation criteria were met for a maximum of 24 months Continuation of study treatment after disease progression will be permitted if there is evidence of clinical benefit for a maximum 24 months
etoposide 80-100 mgm² administered on days 1-3 of each 21-day cycle
investigators choice of either carboplatin area under the curve 5-6 mgmL per min or cisplatin 75-80 mgm² administered on day 1 of each cycle
durvalumab 1500 mg every 3 weeks in combination with chemotherapy induction phase followed by maintenance phase with durvalumab 1500 mg every 4 weeks Patients will continue treatment until disease progression per investigator assessment unacceptable toxicity or other discontinuation criteria were met for a maximum of 24 months Continuation of study treatment after disease progression will be permitted if there is evidence of clinical benefit for a maximum 24 months
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None